Iparomlimab and Tuvonralimab Combined With Nimotuzumab in Recurrent or Metastatic NPC After First-line Treatment Failure: A Single-arm Phase IIa Clinical Trial

This study is testing a combination of three immunotherapy drugs — iparomlimab, tuvonralimab, and nimotuzumab — in people with nasopharyngeal cancer (a type of head and neck cancer) that has come back or spread after first-line chemotherapy. **You may be eligible if...** - You are between 18 and 70 years old - You have been diagnosed with nasopharyngeal carcinoma confirmed by biopsy - Your cancer has come back locally, spread to other parts of the body, or was diagnosed at an advanced stage from the start - Your cancer has failed first-line platinum-based chemotherapy (with or without immunotherapy) - You have at least one measurable tumor on MRI **You may NOT be eligible if...** - Your overall health is too poor (ECOG performance score above 1) - Your liver, kidneys, or blood counts are outside safe ranges - You have active autoimmune disease or are on steroids Talk to your doctor to see if this trial is right for you.